COVID-19 antiviral therapy for non-hospitalized immunosuppressed patients with rheumatic diseases is feasible with positive outcomes.

Lin, Chung M A; Bennett, Josh; Rajagopala, Lavanya; Hunter, Ewan; Lorenzi, Alice R; Griffiths, Bridget; Baker, Kenneth F

Lin, Chung M A; Bennett, Josh; Rajagopala, Lavanya; Hunter, Ewan; Lorenzi, Alice R; Griffiths, Bridget; Baker, Kenneth F.

Lin CMA; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.
Bennett J; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.
Rajagopala L; Musculoskeletal Unit, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
Hunter E; Department of Infectious Diseases, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
Lorenzi AR; Musculoskeletal Unit, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
Griffiths B; Musculoskeletal Unit, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
Baker KF; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.

Rheumatology (Oxford) ; 62(6): e185-e187, 2023 06 01.

Article in English | MEDLINE | ID: covidwho-20238724

Subject(s)

Antirheumatic Agents; COVID-19; Rheumatic Diseases; Humans; Rheumatic Diseases/drug therapy; Antirheumatic Agents/therapeutic use; Antiviral Agents/therapeutic use

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Rheumatic Diseases / Antirheumatic Agents / COVID-19 Limits: Humans Language: English Journal: Rheumatology (Oxford) Journal subject: Rheumatology Year: 2023 Document Type: Article Affiliation country: Rheumatology

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google